Clinical trials: Acute Inflammatory Response
Severe Periodontitis, Acute Inflammatory Response
IFI16 is a Periodontitis Modulating Protein
To characterize the expression of Interferon gamma inducible protein 16 (IFI16) and Absent in melanoma 2 (AIM2) in gingival tissues in an inflammatory response using an acrylic mouthguard (also referred to as a stent) induced…
- Trial name
- IFI (NCT03513497)
- Testing
- Customized acrylic mouthguard
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Acute Kidney Injury
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
- Trial name
- STOP-AKI (NCT02182440)
- Testing
- recAP
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 301 people
- Sponsor
- AM-Pharma
Inflammation
Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans
We aim to examine the extent to which inflammation is affected by acute and chronic opioid exposure.
- Trial name
- NCT01749826
- Testing
- Morphine Sulfate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Stanford University
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various…
- Conditions
- Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia
- Trial name
- STOP-NT (NCT01734694)
- Testing
- Vancomycin, Ceftaroline, Daptomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Henry Ford Health System
Sepsis, Acute Lung Injury
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS.
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01438853
- Testing
- TNX-832
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Altor BioScience
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Lung Injury, Sepsis
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced…
- Trial name
- CITRIS-ALI (NCT02106975)
- Testing
- Ascorbic Acid
- Where
- 5 sites in United States
- Volunteers
- 170 people
- Sponsor
- Virginia Commonwealth University
COVID-19
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
- Trial name
- PREVENT (NCT04365257)
- Testing
- Prazosin, Standard of care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Sepsis, Delirium
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in…
- Conditions
- Sepsis, Delirium, Impaired Cognition
- Trial name
- MENDS2 (NCT01739933)
- Testing
- Dexmedetomidine, Propofol
- Where
- 11 sites in United States
- Volunteers
- 438 people
- Sponsor
- Vanderbilt University Medical Center
Acute Kidney Injury Due to Sepsis
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
The purpose of this study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a…
- Trial name
- NCT05507437
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 7 sites in Belgium, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Gram-Negative Bacterial Infections, Sepsis
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.
- Trial name
- NCT00490477
- Testing
- Polymyxin -B fiber hemoperfusion system
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Turin, Italy
Septic Shock, Acute Kidney Injury
Renin and Renal Biomarker Response to Angiotensin II
Septic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study.
- Trial name
- NCT04558359
- Testing
- Standard of Care, Angiotensin II
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alexander Flannery
Intra-Abdominal Infections, Intestinal Obstruction
Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients
In this study the investigators going to evaluate the "CLI" as an early prognostic indicator for post-operative abdominal sepsis in critically ill patients.
- Conditions
- Intra-Abdominal Infections, Intestinal Obstruction, Appendicitis Acute, Perforated Viscus
- Trial name
- CLI (NCT06901544)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
Acute Respiratory Distress Syndrome, Critical Illness
Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with…
- Conditions
- Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
- Trial name
- ASTER (NCT04291508)
- Testing
- Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature)
- Where
- 41 sites in United States
- Volunteers
- 488 people
- Sponsor
- Massachusetts General Hospital
Necrotizing Soft Tissue Infection, Sepsis
HAT for the Treatment of Sepsis Associated With NASTI
Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.
- Trial name
- NCT05157360
- Testing
- HAT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ascension Health
Acute Respiratory Distress Syndrome, Sepsis
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04870125
- Testing
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota